Viewing Study NCT05993234


Ignite Creation Date: 2025-12-25 @ 2:32 AM
Ignite Modification Date: 2025-12-28 @ 11:20 PM
Study NCT ID: NCT05993234
Status: RECRUITING
Last Update Posted: 2025-12-11
First Post: 2023-08-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module